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Background: Major bleeding increases risk for adverse events following PCI. The
frequency and impact of less severe, or nuisance bleeding, on adverse events after PCI
remains unknown.
Methods: PARIS was a multinational, prospective registry of patients prescribed DAPT
following PCI for any indication from 2009 to 2010 (n¼5,018). Nuisance bleeding was
deﬁned as Bleeding Academic Research Consortium (BARC) type 1. Minor or major
bleeding included BARC  2. Patients were categorized by bleeding severity. Associa-
tions between bleeding and adverse events were examined using Cox regression with
bleeding entered as a time-update covariate. All events were independently adjudicated.
Results: Over 2 years, the cumulative occurrence of nuisance bleeding was 18.0%
(n¼835). Compared to those with more severe bleeding (n¼ 401, 8.3%), patients with
nuisance bleeding were younger, less often female and less likely to receive triple
therapy on discharge. Two-year rates of ischemic adverse events (def/prob stent
thrombosis, myocardial infarction or cardiac death) were 5.6%, 4.9% and 20.1%
among those with none, nuisance, and minor/major bleeding, respectively. Results
were unchanged after multivariable adjustment (Table).
MI-myocardial infarction; Models adjusted for age, gender, region, acute coronary
syndrome, stent type, warfarin use. Adjusted Hazard ratios calculated from Cox
Models with bleeding entered as a time-updated covariate.Table. Hazard Ratios (95% Conﬁdence Intervals) for Ischemic Events
Associated with Bleeding Severity
Spontaneous MI Cardiac Death MACE
No Bleed 1.0 (ref) 1.0 (ref) 1.0 (ref)
Nuisance Bleed 1.19 (0.65-2.17) 0.63 (0.25-1.55) 0.91 (0.54-1.51)
Minor/Major Bleed 2.70 (1.68-4.32) 4.28 (2.82-6.47) 2.82 (2.0-3.98)
MI-myocardial infarction; Models adjusted for age, gender, region, acute coronary syndrome,
stent type, warfarin use. Adjusted Hazard ratios calculated from Cox Models with bleeding
entered as a time-updated covariate.Conclusions: Although common, nuisance bleeding is not associated with an
increased risk for ischemic adverse events following PCI.
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Background: Acute coronary syndromes (ACS) remain the leading cause of out-of-
hospital cardiac arrest (OHCA). Current guidelines plead for early coronary angiog-
raphy and ad-hoc primary percutaneous coronary intervention (PCI). But after cardiac
arrest, shock, hypothermia and modiﬁcation in antiplatelet pharmacokinetic may
promote stent thrombosis (ST). The aim of this study was to evaluate incidence of ST
in survivors of OHCA successfully revascularized with stent implantation.
Methods: We conducted a retrospective observational analysis of all OHCA survivors
with successful PCI between 2011 and 2013. All patients were treated with mild
therapeutic hypothermia for 24h, and dual antiplatelet therapy according to current
guidelines. Clinical, angiographic and biological data were collected. Deﬁnite and
probable ST were reported according to the Academic Research Consortium deﬁnition.
Results: A total of 101 consecutive patients have been included in the present anal-
ysis. Mean age was 61.3 years. 75% of patients had initial ventricular ﬁbrillation.
Mean no ﬂow and low ﬂow were 4.0 +/- 4.3 min and 18.2+/-11.4 min, respectively.
All patients received aspirin before PCI. P2Y12 inhibitors were initiated after stent
implantation and include clopidogrel (48%), prasugrel (22%) or ticagrelor (30%). In
addition, 31% also received GpIIbIIIa inhibitors. The initial TIMI ﬂow was 0 or 1 in
53% of patients. Mean post-procedural left ventricular ejection fraction was 39.6+/-
12.4 %. Global survival rate at discharge was 45%. We identiﬁed 11 cases (10.9%) of
deﬁnite or probable ST (acute, n¼4 and subacute n¼7) with median delay to PCI of 2
days. Stent thrombosis occurred with clopidogrel (n¼2), prasugrel (n¼4) and tica-
grelor (n¼5). Mortality was higher in patients with ST (82% vs 52%; p¼0.06). We
reported more ST with new P2Y12 inhibitors compared to clopidogrel (17 % vs 4 %;
respectively, p¼0.05). Moreover no beneﬁt was observed with the use of pre-treat-
ment with aspirin (p¼0.94) or heparin (p¼0.75).JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/PhaConclusions: IncidenceofST inOHCAsurvivors is highand associatedwith poor clinical
outcome. Optimal antithrombotic therapy in this critical state remains to be determined.
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Background: Dual antiplatelet therapy, aspirin in combination with a P2Y12
antagonist, has been shown to reduce occurrence of ischemic events after coronary
stent implantation in randomized clinical trials. We compared 1-year risk of stent
thrombosis among patients with acute coronary syndromes (ACS) having either pri-
mary percutaneous coronary intervention (PCI) due to ST-segment elevation
myocardial infarction (STEMI) or sub-acute PCI due to non-STEMI or unstable
angina pectoris and dual antiplatelet therapy with either ticagrelor or clopidogrel for
12 months.
Methods: From June 2010 to June 2012 all ACS patients treated with PCI at Odense
University Hospital were identiﬁed from the Western Denmark Heart Registry. From
June 2010 to June 2011 the standard dual antiplatelet therapy was aspirin and clo-
pidogrel (600-mg loading dose, 75 mg daily thereafter): “clopidogrel group” and from
June 2011 to June 2012 the standard dual antiplatelet therapy was changed to aspirin
and ticagrelor (180-mg loading dose, 90 mg twice daily thereafter): “ticagrelor group”.
We assessed the 1-year risk of deﬁnite stent thrombosis after PCI with stent im-
plantation including risk of acute, subacute and late deﬁnite stent thrombosis.
Results: The study cohort consisted of 2,335 patients withACS, ofwhom1,134 patients
were in the “ticagrelor group” and 1,201 patients were in the “clopidogrel group”. The 1-
year risk rate of deﬁnite stent thrombosis was reduced signiﬁcantly in the “ticagrelor
group” n¼5 (0.5%) compared to the “clopidogrel group” n¼17 (1.4%) [hazard ratio
(HR)¼0.31 95% conﬁdence interval (CI) 0.11-0.84]. Ticagrelor reduced especially the
rate of early (within 30 days) deﬁnite stent thrombosis compared with clopidogrel: n¼4
(0.4%) versus n¼15 (1.2%); [HR¼ 0.28 95% CI 0.09-0.85] with a numerically lower
number of acute (n¼1 (0.1%) vs. n¼5 (0.4%), p¼0.219) and subacute (n¼3 (0.3%) vs.
n¼10 (0.8%), p¼0.093) whereas risk of late deﬁnite stent thrombosis did not differ
between ticagrelor n¼1 (0.1%) and clopidogrel n¼2 (0.2%) treated patients.
Conclusions: In a real world setting, treatment with ticagrelor as compared with
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Background: Few studies have examined the safety and effectiveness of prasugrel vs.
clopidogrel in the context of bivalirudin vs. heparin use.
Methods: We evaluated 10,493 STEMI and NSTEMI patients treated with percutaneous
coronary intervention (PCI) at 230 hospitals in the TRANSLATE-ACS observational
study from 4/2010–10/2012. Patients were stratiﬁed based on anticoagulant (bivalirudin
vs. heparinGPI) and antiplatelet (prasugrel vs. clopidogrel) treatment. Outcomes of 30-
day GUSTO-deﬁned bleeding and MACE (death, MI, stroke, or unplanned revasculari-
zation) were compared between groups propensity matched for treatment.
Results: In the overall study population, there were signiﬁcant differences in patient
characteristics, such as age, sex, prior MI, prior CABG, diabetes, STEMI presentation,
and coronary disease burden, between observed treatment groups. After 1:1 propensity
matching, these characteristics were well-balanced between each set of comparison
groups (Cramers F < 0.05). In propensity matched comparisons, the risk of bleeding
was lower among bivalirudin-treated patients compared with those who received
heparinGPI (Table). The 30-day risk of GUSTO bleeding was not signiﬁcantly
different between prasugrel and clopidogrel among bivalirudin-treated patients, nor
among heparin-treated patients. The 30-day risk of MACE was also similar between
prasugrel and clopidogrel regardless of bivalirudin or heparin use.
Conclusions: In routine practice, the patterns of use are quite different in patients treated
with these antiplatelet and anticoagulant therapies. However, 30-day outcomes were not
signiﬁcantly different between prasugrel and clopidogrel, regardless of anticoagulant
choice. Bleeding risk was lower with bivalirudin regardless of antiplatelet choice.rmacotherapy - Aspirin, Thienopyridines and other Platelet Inhibitors B145
